Major Milestone Met in AI-Powered Fight Against Lung Cancer Global initiative gains significant ground in digitally identifying cancer risk before s...
“We are proud to reach this incredible milestone of more than 100,000 patients with the support of our surgeon partners worldwide,” said Exacte...
TBI is an urgent and prominent public health challenge, impacting millions each year as a result of head trauma from accidents, falls, sports-related incid...
Approval is the culmination of ten years of clinical research and development of the Medtronic renal denervation technology Medtronic plc (NYSE: MDT), a ...
Royal Philips (NYSE: PHG, AEX: PHIA) a global leader in health technology, and NYU Langone Health, the nation’s top-ranked academic medical cen...
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central...
QIAGEN announced the expansion of its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing d...
These loose cortical fibers are engineered to complement specific surgical applications in the foot and ankle and are flexible upon hydration allowing for ...
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an eq...
Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease bioma...
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces a collaboration with Uli...
Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in ...
Olympus assessed the issue after receiving complaints of adverse events involving serious patient injury, where patients may suffer burns to the airway or ...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...
© 2025 Biopharma Boardroom. All Rights Reserved.
